The largest study of its kind, involving over 57,000 participants, has uncovered new insights into the genetic factors contributing to severe cases of COVID-19. The GenOMICC consortium, led by the University of Edinburgh and Genomics England, sequenced the genomes of critically ill patients and identified 16 new genetic variants associated with severe COVID-19. These variants are related to blood clotting, immune response, and inflammation intensity. The findings provide a roadmap for future research and offer potential targets for therapeutic interventions and diagnostics. The study’s comprehensive analysis demonstrates the power of genomic sequencing in understanding the mechanisms of COVID-19 and could aid in the development of more effective treatments.
Syed Kamall, Minister for innovation at the Department of Health and Social Care, highlights how:
“Clinical research has been vital in our fight against Covid-19 and the UK’s innovation is enabling us to transform our health service and ensure the NHS is able to deliver world-class care.
This research is an important step forward in better understanding how Covid-19 impacts certain people, allowing us to take the necessary action to protect the most vulnerable and save lives.”
Read more here:
University Hospitals Bristol and Weston NHS Foundation Trust
You must be logged in to post a comment.